{"id":37351,"date":"2026-02-11T14:24:51","date_gmt":"2026-02-11T14:24:51","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/small-molecule-drug-discovery-market-mordor\/"},"modified":"2026-09-11T17:12:48","modified_gmt":"2026-09-11T08:12:48","slug":"small-molecule-drug-discovery-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/small-molecule-drug-discovery-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \uc800\ubd84\uc790 \uc2e0\uc57d \uac1c\ubc1c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026-2031)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/small-molecule-drug-discovery-market_1709690597319_small_.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/small-molecule-drug-discovery-market-size-image-1767942755781.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 \ub9cc\uc131 \ubc0f \ub178\ud654 \uad00\ub828 \uc9c8\ubcd1 \ubd80\ub2f4 \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.2.2 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ub300\ube44 \uc6b0\uc218\ud55c \uc81c\uc870 \uac00\ub2a5\uc131 \ubc0f \ube44\uc6a9 \ud6a8\uc728\uc131<\/li>\n<li class=\"toc-level-3\">4.2.3 AI \uae30\ubc18 \ud788\ud2b8-\ud22c-\ub9ac\ub4dc \ubaa8\ub378\ub9c1\uc758 \ube60\ub978 \ubc1c\uc804<\/li>\n<li class=\"toc-level-3\">4.2.4 \uc2b9\uc778 \uac00\uc18d\ud654\ub97c \uc704\ud55c \uaddc\uc81c \uc2e0\uc18d \uc2ec\uc0ac \uc9c0\uc815<\/li>\n<li class=\"toc-level-3\">4.2.5 \uc628\ub514\ub9e8\ub4dc GMP \ud569\uc131\uc744 \uac00\ub2a5\ud558\uac8c \ud558\ub294 \ubbf8\ub2c8 \ud50c\ub85c\uc6b0 \ud654\ud559<\/li>\n<li class=\"toc-level-3\">4.2.6 \uc591\uc790 \ucef4\ud4e8\ud305 \ubd84\uc790 \uc2dc\ubbac\ub808\uc774\uc158\uc758 \ud601\uc2e0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778\n<ul>\n<li class=\"toc-level-3\">4.3.1 \ud6c4\uae30 \ub2e8\uacc4 \uc2e4\ud328 \ubc0f \ube44\uc6a9 \uc778\ud50c\ub808\uc774\uc158 \uc2ec\ud654<\/li>\n<li class=\"toc-level-3\">4.3.2 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ubc0f \ucca8\ub2e8 \uce58\ub8cc\uc81c\ub85c\uc758 \uc790\ubcf8 \uc804\ud658<\/li>\n<li class=\"toc-level-3\">4.3.3 \ud569\uc131 \uc2dc \uc6a9\ub9e4 \ubc30\ucd9c\uc5d0 \ub300\ud55c ESG \uac10\uc2dc<\/li>\n<li class=\"toc-level-3\">4.3.4 \ud76c\uadc0 \uad11\uc0b0\ud654\ud658\uc6d0 \ucd09\ub9e4\uc758 \uacf5\uae09 \uc704\ud5d8<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \uaddc\uc81c \ud658\uacbd<\/li>\n<li class=\"toc-level-2\">4.5 \uae30\uc220 \uc804\ub9dd<\/li>\n<li class=\"toc-level-2\">4.6 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778\n<ul>\n<li class=\"toc-level-3\">4.6.1 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.6.2 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.6.3 \uacf5\uae09\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.6.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.6.5 \uacbd\uc7c1 \uac15\ub3c4<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (\uac00\uce58, USD)<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \uce58\ub8cc \ubd84\uc57c\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.1.1 \uc885\uc591\ud559<\/li>\n<li class=\"toc-level-3\">5.1.2 \uc911\ucd94\uc2e0\uacbd\uacc4<\/li>\n<li class=\"toc-level-3\">5.1.3 \uc2ec\ud608\uad00<\/li>\n<li class=\"toc-level-3\">5.1.4 \ud638\ud761\uae30<\/li>\n<li class=\"toc-level-3\">5.1.5 \ub300\uc0ac \uc7a5\uc560<\/li>\n<li class=\"toc-level-3\">5.1.6 \uc704\uc7a5<\/li>\n<li class=\"toc-level-3\">5.1.7 \uac10\uc5fc\uc131 \uc9c8\ud658<\/li>\n<li class=\"toc-level-3\">5.1.8 \uc790\uac00\uba74\uc5ed \uc9c8\ud658<\/li>\n<li class=\"toc-level-3\">5.1.9 \uae30\ud0c0 \uce58\ub8cc \ubd84\uc57c<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \ubc1c\uacac \ub2e8\uacc4\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.2.1 \ud45c\uc801 \uc2dd\ubcc4 \ubc0f \uac80\uc99d<\/li>\n<li class=\"toc-level-3\">5.2.2 \ud788\ud2b8 \uc0dd\uc131 \ubc0f \uc120\ud0dd<\/li>\n<li class=\"toc-level-3\">5.2.3 \uc120\ub3c4 \ubb3c\uc9c8 \uc2dd\ubcc4<\/li>\n<li class=\"toc-level-3\">5.2.4 \uc120\ub3c4 \ubb3c\uc9c8 \ucd5c\uc801\ud654<\/li>\n<li class=\"toc-level-3\">5.2.5 \uc804\uc784\uc0c1 \ud6c4\ubcf4 \ubb3c\uc9c8 \uc120\ud0dd<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \uc57d\ubb3c \uc720\ud615\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.3.1 \ud569\uc131 \uc800\ubd84\uc790 \ud654\ud569\ubb3c<\/li>\n<li class=\"toc-level-3\">5.3.2 \ucc9c\uc5f0\ubb3c \uc720\ub3c4\uccb4<\/li>\n<li class=\"toc-level-3\">5.3.3 \ud3a9\ud0c0\uc774\ub4dc \ubaa8\ubc29\uccb4<\/li>\n<li class=\"toc-level-3\">5.3.4 PROTAC \ubc0f \ubd84\uc790 \uc811\ucc29\uc81c<\/li>\n<li class=\"toc-level-3\">5.3.5 \ub274\ud074\ub808\uc624\uc0ac\uc774\ub4dc \uc720\uc0ac\uccb4<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \uae30\uc220\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.4.1 \uace0\uc18d \uc2a4\ud06c\ub9ac\ub2dd (HTS)<\/li>\n<li class=\"toc-level-3\">5.4.2 \ub2e8\ud3b8 \uae30\ubc18 \uc2e0\uc57d \uac1c\ubc1c (FBDD)<\/li>\n<li class=\"toc-level-3\">5.4.3 \uad6c\uc870 \uae30\ubc18 \uc57d\ubb3c \uc124\uacc4 (SBDD)<\/li>\n<li class=\"toc-level-3\">5.4.4 \uacc4\uc0b0\/AI \uae30\ubc18 \uc124\uacc4<\/li>\n<li class=\"toc-level-3\">5.4.5 DNA \uc778\ucf54\ub529 \ub77c\uc774\ube0c\ub7ec\ub9ac \uc2a4\ud06c\ub9ac\ub2dd<\/li>\n<li class=\"toc-level-3\">5.4.6 CRISPR \uae30\ubc18 \ud45c\uc801 \uac80\uc99d<\/li>\n<li class=\"toc-level-3\">5.4.7 \uc0dd\uccb4 \ubd84\uc11d \uac1c\ubc1c \ubc0f \uc138\ud3ec \uae30\ubc18 \ud50c\ub7ab\ud3fc<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.5 \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.5.1 \uc81c\uc57d \ud68c\uc0ac<\/li>\n<li class=\"toc-level-3\">5.5.2 \uc0dd\uba85\uacf5\ud559 \ud68c\uc0ac<\/li>\n<li class=\"toc-level-3\">5.5.3 \ud559\uc220 \ubc0f \uc5f0\uad6c \uae30\uad00<\/li>\n<li class=\"toc-level-3\">5.5.4 \uacc4\uc57d \uc5f0\uad6c \uae30\uad00 (CRO)<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.6 \uc9c0\uc5ed\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.6.1 \ubd81\ubbf8\n<ul>\n<li class=\"toc-level-4\">5.6.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-4\">5.6.1.3 \uba55\uc2dc\ucf54<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.2 \uc720\ub7fd\n<ul>\n<li class=\"toc-level-4\">5.6.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.6.2.2 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.2.3 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.6.2.4 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.6.2.5 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.6.2.6 \uae30\ud0c0 \uc720\ub7fd<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\n<ul>\n<li class=\"toc-level-4\">5.6.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.3.2 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.6.3.3 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.6.3.4 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.3.5 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.6.3.6 \uae30\ud0c0 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.4 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74\n<ul>\n<li class=\"toc-level-4\">5.6.4.1 GCC<\/li>\n<li class=\"toc-level-4\">5.6.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.6.4.3 \uae30\ud0c0 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.5 \ub0a8\ubbf8\n<ul>\n<li class=\"toc-level-4\">5.6.5.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.6.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.6.5.3 \uae30\ud0c0 \ub0a8\ubbf8<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uc218\uc900 \uac1c\uc694, \uc2dc\uc7a5 \uc218\uc900 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34, \uc804\ub7b5 \uc815\ubcf4, \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 &amp; \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)\n<ul>\n<li class=\"toc-level-3\">6.3.1 AstraZeneca plc<\/li>\n<li class=\"toc-level-3\">6.3.2 Atomwise Inc.<\/li>\n<li class=\"toc-level-3\">6.3.3 BenevolentAI<\/li>\n<li class=\"toc-level-3\">6.3.4 Charles River Laboratories<\/li>\n<li class=\"toc-level-3\">6.3.5 ChemPartner<\/li>\n<li class=\"toc-level-3\">6.3.6 Curia Global Inc.<\/li>\n<li class=\"toc-level-3\">6.3.7 Domainex Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.8 Eurofins Discovery<\/li>\n<li class=\"toc-level-3\">6.3.9 Evotec SE<\/li>\n<li class=\"toc-level-3\">6.3.10 Exscientia plc<\/li>\n<li class=\"toc-level-3\">6.3.11 GenScript Biotech<\/li>\n<li class=\"toc-level-3\">6.3.12 ICON plc<\/li>\n<li class=\"toc-level-3\">6.3.13 Insilico Medicine<\/li>\n<li class=\"toc-level-3\">6.3.14 Jubilant Biosys Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.15 Labcorp Drug Development<\/li>\n<li class=\"toc-level-3\">6.3.16 Pfizer Inc.<\/li>\n<li class=\"toc-level-3\">6.3.17 Recursion Pharmaceuticals<\/li>\n<li class=\"toc-level-3\">6.3.18 Relay Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.19 Schrodinger Inc.<\/li>\n<li class=\"toc-level-3\">6.3.20 Syngene International Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.21 Thermo Fisher Scientific Inc.<\/li>\n<li class=\"toc-level-3\">6.3.22 WuXi AppTec<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c &amp; \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5 \uac1c\uc694 (2026-2031)<\/p>\n<p>Mordor Intelligence\uc758 \ubd84\uc11d\uc5d0 \ub530\ub974\uba74, \uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5\uc740 2026\ub144 674\uc5b5 2\ucc9c\ub9cc \ub2ec\ub7ec\uc5d0\uc11c 2031\ub144 1,030\uc5b5 6\ucc9c\ub9cc \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \uc608\uce21 \uae30\uac04(2026-2031) \ub3d9\uc548 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 8.86%\ub97c \uae30\ub85d\ud560 \uac83\uc785\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uac1c\uc694 \uc694\uc57d:<br \/>\n*   \uc5f0\uad6c \uae30\uac04: 2020\ub144 &#8211; 2031\ub144<br \/>\n*   2026\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 674\uc5b5 2\ucc9c\ub9cc \ub2ec\ub7ec<br \/>\n*   2031\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 1,030\uc5b5 6\ucc9c\ub9cc \ub2ec\ub7ec<br \/>\n*   \uc131\uc7a5\ub960 (2026-2031): 8.86% CAGR<br \/>\n*   \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5: \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<br \/>\n*   \uac00\uc7a5 \ud070 \uc2dc\uc7a5: \ubd81\ubbf8<br \/>\n*   \uc2dc\uc7a5 \uc9d1\uc911\ub3c4: \uc911\uac04<\/p>\n<p>\uc2dc\uc7a5 \ubd84\uc11d \ubc0f \uc8fc\uc694 \ub3d9\ud5a5:<\/p>\n<p>\uacc4\uc0b0 \ud654\ud559\uc758 \ubc1c\uc804, \uc778\uacf5\uc9c0\ub2a5(AI) \uae30\ubc18 \ud45c\uc801 \uc120\ud0dd, \uadf8\ub9ac\uace0 \uaddc\uc81c \uc2e0\uc18d \uc2b9\uc778 \ud504\ub85c\uadf8\ub7a8 \ub4f1\uc774 \uc2e0\uc57d \ubc1c\uad74 \uae30\uac04\uc744 \ub2e8\ucd95\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. 2025\ub144 FDA \uc2b9\uc778 \uc2e0\uc57d 55\uac1c \uc911 \uc808\ubc18 \uc774\uc0c1\uc774 \uc18c\ubd84\uc790 \uc57d\ubb3c\uc774\uc5c8\uc73c\uba70, \uc774\ub294 \ubbf8\ucda9\uc871 \uc758\ub8cc \uc218\uc694 \ud574\uacb0\uc5d0 \uc788\uc5b4 \uc18c\ubd84\uc790\uc758 \ud575\uc2ec\uc801\uc778 \uc5ed\ud560\uc744 \uc7ac\ud655\uc778\uc2dc\ucf1c \uc90d\ub2c8\ub2e4. \uc815\ubc00 \uc758\ud559 \ud504\ub808\uc784\uc6cc\ud06c\uc640 \ubc14\uc774\uc624\ub9c8\ucee4 \uae30\ubc18 \ud658\uc790\uad70 \uc815\ub82c \ub355\ubd84\uc5d0 \uc885\uc591\ud559 \ubd84\uc57c\ub294 \uc9c0\uc18d\uc801\uc778 \uc131\uc7a5\uc744 \ubcf4\uc600\uc73c\uba70, \uc870\uc9c1 \uc120\ud0dd\uc801 \uba74\uc5ed\uc5b5\uc81c \ubd84\uc57c\uc758 \ubc1c\uc804\uc73c\ub85c \uc790\uac00\uba74\uc5ed \ud504\ub85c\uadf8\ub7a8\ub3c4 \ud61c\ud0dd\uc744 \ubc1b\uc558\uc2b5\ub2c8\ub2e4.<\/p>\n<p>PROTACs \ubc0f \ubd84\uc790 \uc811\ucc29\uc81c(molecular glues)\uc640 \uac19\uc740 \uc0c8\ub85c\uc6b4 \ubc29\uc2dd\uc740 \uacfc\uac70 &#8216;\uc57d\ubb3c \ubd88\uac00\ub2a5(undruggable)&#8217;\uc73c\ub85c \uc5ec\uaca8\uc84c\ub358 \ub2e8\ubc31\uc9c8\uccb4 \uc601\uc5ed\uc744 \uac1c\ucc99\ud558\uba70 \uc8fc\ubaa9\ubc1b\uace0 \uc788\uc2b5\ub2c8\ub2e4. AI \uae30\ubc18 \ud50c\ub7ab\ud3fc\uc740 \ud45c\uc801 \ubc1c\uad74\ubd80\ud130 \uc784\uc0c1\uc2dc\ud5d8\uacc4\ud68d(IND) \uc81c\ucd9c\uae4c\uc9c0\uc758 \uc2dc\uac04\uc744 \ucd5c\ub300 40% \ub2e8\ucd95\ud558\ub294 \ub2a5\ub825\uc744 \uc785\uc99d\ud588\uc2b5\ub2c8\ub2e4 (\uc608: REC-1245\uc758 2024\ub144 2\uc0c1 \uc9c4\uc785). \uc9c0\uc5ed\ubcc4\ub85c\ub294 \ubd81\ubbf8\uac00 \uc9c0\ucd9c\uc744 \uc8fc\ub3c4\ud588\uc9c0\ub9cc, \uc911\uad6d\uc758 \uc870\uac74\ubd80 \uc2b9\uc778\uacfc \uc778\ub3c4\uc758 \uacc4\uc57d \uc5f0\uad6c \uc778\ud504\ub77c \ud655\ub300\ub85c \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc774 \uac00\uc7a5 \ube60\ub978 \uc131\uc7a5\uc744 \ubcf4\uc600\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \ubcf4\uace0\uc11c \uc694\uc810:<\/p>\n<p>*   \uce58\ub8cc \ubd84\uc57c\ubcc4: 2025\ub144 \uc885\uc591\ud559\uc774 \uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 31.55%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc790\uac00\uba74\uc5ed \uc9c8\ud658\uc740 2031\ub144\uae4c\uc9c0 12.25%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \ubc1c\uad74 \ub2e8\uacc4\ubcc4: 2025\ub144 \uc120\ub3c4 \ubb3c\uc9c8 \ubc1c\uad74(Lead identification)\uc774 24.53%\uc758 \ub9e4\ucd9c \uc810\uc720\uc728\uc744 \uae30\ub85d\ud588\uc73c\uba70, \uc804\uc784\uc0c1 \ud6c4\ubcf4 \ubb3c\uc9c8 \uc120\uc815(Pre-clinical candidate selection)\uc740 2031\ub144\uae4c\uc9c0 13.85%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub978 \uc131\uc7a5\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<br \/>\n*   \uc57d\ubb3c \uc720\ud615\ubcc4: 2025\ub144 \ud569\uc131 \uc18c\ubd84\uc790(Synthetic compounds)\uac00 43.63%\ub97c \ucc28\uc9c0\ud588\uc9c0\ub9cc, PROTACs \ubc0f \ubd84\uc790 \uc811\ucc29\uc81c\ub294 17.87%\uc758 CAGR\ub85c \ud655\uc7a5\ub420 \uc608\uc815\uc785\ub2c8\ub2e4.<br \/>\n*   \uae30\uc220\ubcc4: 2025\ub144 \uace0\ucc98\ub9ac\ub7c9 \uc2a4\ud06c\ub9ac\ub2dd(HTS)\uc774 30.23%\uc758 \uc810\uc720\uc728\uc744 \uc720\uc9c0\ud588\uc9c0\ub9cc, DNA \uc778\ucf54\ub529 \ub77c\uc774\ube0c\ub7ec\ub9ac \uc2a4\ud06c\ub9ac\ub2dd(DNA-encoded library screening)\uc740 14.7%\uc758 CAGR\ub85c \uc0c1\uc2b9\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: 2025\ub144 \uc81c\uc57d \ud68c\uc0ac\uac00 \uc9c0\ucd9c\uc758 45.3%\ub97c \ucc28\uc9c0\ud588\uc9c0\ub9cc, \uc0dd\uba85\uacf5\ud559 \ud68c\uc0ac\ub294 11.81%\uc758 CAGR\ub85c \uc131\uc7a5\uc744 \uc8fc\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: 2025\ub144 \ubd81\ubbf8\uac00 \ub9e4\ucd9c\uc758 39.53%\ub97c \uae30\uc5ec\ud588\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\uc740 2031\ub144\uae4c\uc9c0 11.21%\uc758 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p>\uae00\ub85c\ubc8c \uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \ud1b5\ucc30\ub825:<\/p>\n<p>\uc131\uc7a5 \ub3d9\ub825:<\/p>\n<p>*   \ub9cc\uc131 \ubc0f \ub178\uc778\uc131 \uc9c8\ud658 \ubd80\ub2f4 \uc99d\uac00 (+1.8% CAGR \uc601\ud5a5): \uc554, \uc2ec\ud608\uad00 \uc9c8\ud658, \ub300\uc0ac \uc7a5\uc560\uac00 \uc2e0\uaddc \ubd84\uc790 \ubb3c\uc9c8(NME) \uc2b9\uc778\uc744 \uc8fc\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. 2030\ub144\uae4c\uc9c0 \ubd81\ubbf8\uc640 \uc720\ub7fd \uc778\uad6c\uc758 20% \uc774\uc0c1\uc774 65\uc138 \uc774\uc0c1\uc774 \ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uc5b4, \uc2e0\uacbd \ud1f4\ud589\uc131 \uc9c8\ud658, \uace8\uad00\uc808\uc5fc \ubc0f \ub3d9\ubc18 \uc9c8\ud658 \uce58\ub8cc\uc81c\uc5d0 \ub300\ud55c \uc218\uc694\uac00 \uc9c0\uc18d\ub420 \uac83\uc785\ub2c8\ub2e4. \uc2a4\ud3f0\uc11c\ub4e4\uc740 \ub178\uc778 \uc57d\ub3d9\ud559 \ubc0f \ub3d9\ubc18 \uc9c8\ud658 \ubaa8\ub378\ub9c1\uc744 \ucd08\uae30 \ub2e8\uacc4\uc5d0 \ud1b5\ud569\ud558\uc5ec \uc804\uc784\uc0c1 \uc9c0\ucd9c\uc744 \ub298\ub9ac\uc9c0\ub9cc \ud6c4\uae30 \ub2e8\uacc4\uc758 \uc2e4\ud328\uc728\uc744 \ub0ae\ucd94\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc790\uac00\uba74\uc5ed \ud504\ub85c\uadf8\ub7a8\uc740 JAK \uc5b5\uc81c\uc81c \ubc0f S1P \uc870\uc808\uc81c\uc758 \uc2e0\uc18d \uc2b9\uc778\uc73c\ub85c \ud61c\ud0dd\uc744 \ubc1b\uace0 \uc788\uc73c\uba70, \uc774\ub294 2031\ub144\uae4c\uc9c0 \uc790\uac00\uba74\uc5ed \uc911\uc2ec \ud30c\uc774\ud504\ub77c\uc778\uc758 \ub450 \uc790\ub9bf\uc218 \uc131\uc7a5\uc744 \ub4b7\ubc1b\uce68\ud569\ub2c8\ub2e4.<br \/>\n*   \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ub300\ube44 \uc6b0\uc218\ud55c \uc81c\uc870 \uc6a9\uc774\uc131 \ubc0f \ube44\uc6a9 \ud6a8\uc728\uc131 (+1.5% CAGR \uc601\ud5a5): \uc18c\ubd84\uc790 \uc57d\ubb3c\uc740 \ucf5c\ub4dc \uccb4\uc778 \ube44\uc6a9, \uc8fc\uc785 \uc778\ud504\ub77c, \ub300\uaddc\ubaa8 \uc0dd\ubb3c \ubc18\uc751\uae30\uac00 \ud544\uc694 \uc5c6\uc5b4 \ub9cc\uc131 \uc9c8\ud658 \uce58\ub8cc \ube44\uc6a9\uc744 40-60% \uc808\uac10\ud569\ub2c8\ub2e4. \ud654\uc774\uc790\ub294 2024\ub144 \uc18c\ubd84\uc790 \ud3ec\ud2b8\ud3f4\ub9ac\uc624\uc758 \uc601\uc5c5 \uc774\uc775\ub960\uc774 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\ubcf4\ub2e4 15% \ud3ec\uc778\ud2b8 \ub192\ub2e4\uace0 \ubc1d\ud614\uc2b5\ub2c8\ub2e4. \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc758 \uc9c0\ubd88\uc790\ub4e4\uc740 \uacbd\uad6c \ud22c\uc5ec \uc81c\ub124\ub9ad\uc744 \uc120\ud638\ud558\ub294 \ud544\uc218 \uc758\uc57d\ud488 \ubaa9\ub85d\uc744 \uc6b0\uc120\uc2dc\ud558\uc5ec \ubb3c\ub7c9 \ud655\ub300\ub97c \uac15\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub300\ud615 \uc81c\uc57d\uc0ac\ub4e4\uc740 \uc790\ubcf8 \uc0dd\uc0b0\uc131\uc744 \ucd5c\uc801\ud654\ud558\uae30 \uc704\ud574 \uc720\ubcd1\ub960\uc774 \ub192\uc740 \uc9c8\ud658\uc5d0 \ub300\ud55c \uacbd\uad6c\uc6a9 \uc81c\uc81c \uc5f0\uad6c \uac1c\ubc1c\ub85c \uade0\ud615\uc744 \uc7ac\uc870\uc815\ud558\uace0 \uc788\uc73c\uba70, \uc774\ub294 8.86%\uc758 CAGR\uc744 \ub4b7\ubc1b\uce68\ud569\ub2c8\ub2e4.<br \/>\n*   AI \uae30\ubc18 \ud788\ud2b8-\ud22c-\ub9ac\ub4dc(Hit-to-Lead) \ubaa8\ub378\ub9c1\uc758 \ube60\ub978 \ubc1c\uc804 (+2.1% CAGR \uc601\ud5a5): Recursion\uc740 AI \uae30\ubc18 \ud788\ud2b8-\ud22c-\ub9ac\ub4dc \ucea0\ud398\uc778\uc744 \ud1b5\ud574 \uc804\uc784\uc0c1 \uc791\uc5c5\uc744 \uc57d 40% \ub2e8\ucd95\ud558\uc5ec REC-1245\ub97c 2\uc0c1\uc73c\ub85c \uc9c4\uc785\uc2dc\ucf30\uc2b5\ub2c8\ub2e4. Insilico Medicine\uc740 2025\ub144 AI\ub85c \ubc1c\uad74\ud55c TNIK \uc5b5\uc81c\uc81c\uc5d0 \ub300\ud55c 2a\uc0c1 \uae0d\uc815\uc801\uc778 \ub370\uc774\ud130\ub97c \ubcf4\uace0\ud558\uba70 \uac1c\ub150 \uc99d\uba85\uc744 \uc81c\uc2dc\ud588\uc2b5\ub2c8\ub2e4. 2024\ub144 FDA\uc758 AI \uc0dd\uc131 \uac00\uc124\uc5d0 \ub300\ud55c \ucd08\uc548 \uc9c0\uce68\uc740 \uaddc\uc81c \ubd88\ud655\uc2e4\uc131\uc744 \uc81c\uac70\ud588\uc2b5\ub2c8\ub2e4. AlphaFold2\uc758 \uc608\uce21 \ub3c4\ud0b9\uc740 2024\ub144 Nature \ubcf4\uace0\uc11c\uc5d0\uc11c \uacf5\ub3d9 \uacb0\uc815 \uad6c\uc870\uac00 \uc5c6\ub294 \ud45c\uc801\uc5d0 \ub300\ud55c \uad6c\uc870 \uae30\ubc18 \uc124\uacc4\ub97c \uc785\uc99d\ud588\uc2b5\ub2c8\ub2e4. \uacb0\uacfc\uc801\uc73c\ub85c \ud22c\uc790\uc790\ub4e4\uc740 \ucc28\ubcc4\ud654\ub41c \uc790\uc0b0\uc744 \uc2e0\uc18d\ud558\uac8c \ubc1c\uad74\ud560 \uc218 \uc788\ub294 AI \uae30\ubc18 \uc0dd\uba85\uacf5\ud559 \uae30\uc5c5\uc5d0 \ud6c4\uae30 \ub2e8\uacc4 \uc790\uae08\uc744 \ud22c\uc785\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uaddc\uc81c \uc2e0\uc18d \uc2b9\uc778 \uc9c0\uc815 \uac00\uc18d\ud654 (+1.2% CAGR \uc601\ud5a5): FDA\ub294 2024\ub144 \uc8fc\ub85c \uc885\uc591\ud559 \ubc0f \ud76c\uadc0 \uc9c8\ud658 \ubd84\uc57c\uc5d0\uc11c 77\uac74\uc758 \ud601\uc2e0 \uce58\ub8cc\uc81c \uc9c0\uc815\uc744 \ubc1c\ud45c\ud588\uc2b5\ub2c8\ub2e4. \uc544\uc81c\ub178\uc138\ub974\ud301(Azenosertib)\uc740 2025\ub144 \uac1d\uad00\uc801 \ubc18\uc751 \ub370\uc774\ud130\ub9cc\uc73c\ub85c \ubc31\uae08 \ub0b4\uc131 \ub09c\uc18c\uc554\uc5d0 \ub300\ud55c \uac00\uc18d \uc2b9\uc778\uc744 \ubc1b\uc558\uc2b5\ub2c8\ub2e4. EMA\uc758 PRIME \ud504\ub85c\uadf8\ub7a8\uc740 2024\ub144 12\uac1c\uc758 \uc18c\ubd84\uc790 \uc790\uc0b0\uc5d0 \uc801\uaca9\uc131\uc744 \ubd80\uc5ec\ud558\uc5ec \uc21c\ucc28\uc801 \uac80\ud1a0\ub97c \ucd09\uc9c4\ud588\uc2b5\ub2c8\ub2e4. \uc911\uad6d\uc758 \uc790\uad6d\uc0b0 \ubd84\uc790\uc5d0 \ub300\ud55c \uc870\uac74\ubd80 \uc2b9\uc778 \uacbd\ub85c\ub294 \uad6d\ub0b4 \uac1c\ubc1c\uc744 \ucd09\uc9c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc2a4\ud3f0\uc11c\ub4e4\uc740 \uc774\ub7ec\ud55c \uc2e0\uc18d \ud504\ub808\uc784\uc6cc\ud06c\uc5d0 \ub9de\ucdb0 \uc801\uc751\ud615 \uc784\uc0c1\uc2dc\ud5d8 \ubc0f \ubc14\uc774\uc624\ub9c8\ucee4 \uae30\ubc18 \ud3c9\uac00 \ubcc0\uc218\ub97c \uc124\uacc4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc628\ub514\ub9e8\ub4dc \ud569\uc131\uc744 \uc704\ud55c \ubbf8\ub2c8 \ud50c\ub85c\uc6b0 \ud654\ud559 (+0.9% CAGR \uc601\ud5a5)<br \/>\n*   \uc591\uc790 \ucef4\ud4e8\ud305 \ubd84\uc790 \uc2dc\ubbac\ub808\uc774\uc158 (+0.6% CAGR \uc601\ud5a5)<\/p>\n<p>\uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778:<\/p>\n<p>*   \ud6c4\uae30 \ub2e8\uacc4 \uc2e4\ud328 \ubc0f \ube44\uc6a9 \uc778\ud50c\ub808\uc774\uc158 \uc2ec\ud654 (-1.4% CAGR \uc601\ud5a5): 2024-2025\ub144 \uc5ec\ub7ec \uc885\uc591\ud559 \ud6c4\ubcf4 \ubb3c\uc9c8\uc774 \uc548\uc804\uc131 \ub610\ub294 \ud6a8\ub2a5 \uaca9\ucc28\ub85c \uc778\ud574 \uc644\uc804 \ubc18\uc751 \uc11c\ud55c(complete response letters)\uc744 \ubc1b\uc544 3\uc0c1 \uc2e4\ud328\uc728\uc774 \uc5ec\uc804\ud788 \ub192\uc2b5\ub2c8\ub2e4. \uc2a4\ud3f0\uc11c\ub4e4\uc740 IND \uc804\uc5d0 \uac15\ub825\ud55c \uc0dd\uccb4 \ub0b4 \ub370\uc774\ud130 \ubc0f \uc911\uac1c \ubc14\uc774\uc624\ub9c8\ucee4\ub97c \uc694\uad6c\ud558\uc5ec \uc804\uc784\uc0c1 \uc9c0\ucd9c\uc744 \ub298\ub9ac\uc9c0\ub9cc \ud6c4\uae30 \ub2e8\uacc4 \uc704\ud5d8\uc744 \ub0ae\ucd94\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud6c4\uae30 \ub2e8\uacc4 \uc2e4\ud328\ub97c \uac10\ub2f9\ud560 \uc218 \uc5c6\ub294 \uc18c\uaddc\ubaa8 \uc0dd\uba85\uacf5\ud559 \uae30\uc5c5\ub4e4\uc740 \ud1b5\ud569 \uc555\ub825\uc5d0 \uc9c1\uba74\ud574 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ubc0f \ucca8\ub2e8 \uce58\ub8cc\ubc95\uc73c\ub85c\uc758 \uc790\ubcf8 \uc804\ud658 (-1.1% CAGR \uc601\ud5a5): 2024-2025\ub144 M&#038;A \ubc0f \ubca4\ucc98 \uc790\uae08\uc740 \uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c \uc790\uc0b0\uc5d0 \uc9d1\uc911\ub418\uc5b4, \uc804\ud1b5\uc801\uc778 \uc758\uc57d \ud654\ud559 \ud504\ub85c\uadf8\ub7a8\uc740 \uc790\ubcf8 \ud655\ubcf4\uc5d0 \uc5b4\ub824\uc6c0\uc744 \uacaa\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud22c\uc790\uc790\ub4e4\uc740 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\uc5d0\uc11c \ub354 \uac15\ub825\ud55c \ud2b9\ud5c8 \uc7a5\ubcbd\uacfc \uac00\uaca9 \uacb0\uc815\ub825\uc744 \uc778\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc18c\ubd84\uc790 \ud300\uc740 \uacbd\uad6c \uc0dd\uccb4 \uc774\uc6a9\ub960, \uc911\ucd94\uc2e0\uacbd\uacc4 \uce68\ud22c, \ub0ae\uc740 \uc81c\uc870 \ube44\uc6a9\uc744 \uac15\uc870\ud558\uac70\ub098, \uc18c\ubd84\uc790\uc758 \uc7a5\uc810\uacfc \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \uc218\uc900\uc758 \uc120\ud0dd\uc131\uc744 \uacb0\ud569\ud55c \ubd84\ud574\uc81c(degraders)\ub85c \uc804\ud658\ud558\uc5ec \ub300\uc751\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc6a9\ub9e4 \ubc30\ucd9c\uc5d0 \ub300\ud55c ESG \uc870\uc0ac (-0.5% CAGR \uc601\ud5a5)<br \/>\n*   \ud76c\uadc0 \uad11\uc0b0\ud654 \ucd09\ub9e4 \uacf5\uae09 \uc704\ud5d8 (-0.3% CAGR \uc601\ud5a5)<\/p>\n<p>\uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d:<\/p>\n<p>*   \uce58\ub8cc \ubd84\uc57c\ubcc4: \uc885\uc591\ud559\uc740 2025\ub144 \ub9e4\ucd9c\uc758 31.55%\ub97c \ucc28\uc9c0\ud558\uba70 \uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5\uc5d0\uc11c \uac00\uc7a5 \ud070 \ube44\uc911\uc744 \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uc790\uac00\uba74\uc5ed \uc9c8\ud658\uc740 \ucc28\uc138\ub300 JAK \uc5b5\uc81c\uc81c \ubc0f S1P \uc218\uc6a9\uccb4 \uc870\uc808\uc81c \uc2b9\uc778\uc5d0 \ud798\uc785\uc5b4 12.25%\uc758 CAGR\ub85c \ub2e4\ub978 \ubaa8\ub4e0 \uc801\uc751\uc99d\uc744 \ub2a5\uac00\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc870\uc9c1 \uc120\ud0dd\uc801 \uba74\uc5ed\uc5b5\uc81c \uac1c\uc120\uc73c\ub85c \uc548\uc804\uc131 \ud504\ub85c\ud30c\uc77c\uc774 \ud5a5\uc0c1\ub428\uc5d0 \ub530\ub77c \uc790\uac00\uba74\uc5ed \uc9c8\ud658\uc5d0 \ub300\ud55c \uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5 \uaddc\ubaa8\ub294 \ube60\ub974\uac8c \ud655\uc7a5\ub420 \uac83\uc785\ub2c8\ub2e4. \uc911\ucd94\uc2e0\uacbd\uacc4 \ud30c\uc774\ud504\ub77c\uc778\uc740 \uc54c\uce20\ud558\uc774\uba38\ubcd1 \ubc0f \ub09c\uce58\uc131 \uc6b0\uc6b8\uc99d \uce58\ub8cc\ub97c \uc704\ud574 NMDA \uc870\uc808 \ubc0f \uc2e0\uacbd \uc5fc\uc99d\uc744 \ud45c\uc801\uc73c\ub85c \ud558\uba70, \uc2ec\ud608\uad00 \ud504\ub85c\uadf8\ub7a8\uc740 SGLT2 \ubc0f GLP-1 \uba54\ucee4\ub2c8\uc998\uc744 \ud65c\uc6a9\ud558\uc5ec \uc2ec\ud608\uad00-\ub300\uc0ac \uc774\uc810\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \ud638\ud761\uae30 \uc5f0\uad6c\ub294 COPD \ubc0f \ub0ad\ud3ec\uc131 \uc12c\uc720\uc99d\uc758 \uae30\ub3c4 \uc7ac\ud615\uc131\uc5d0 \ucd08\uc810\uc744 \ub9de\ucd94\uace0 \uc788\uc73c\uba70, \uc704\uc7a5 \ud504\ub85c\uc81d\ud2b8\ub294 IBS \ubc0f \ud06c\ub860\ubcd1\uc5d0 \ub300\ud55c \ub9c8\uc774\ud06c\ub85c\ubc14\uc774\uc634 \uc870\uc808 \ud654\ud569\ubb3c\uc744 \ucd94\uad6c\ud569\ub2c8\ub2e4. \ud56d\uc0dd\uc81c \ub0b4\uc131 \ubb38\uc81c\ub85c \uc778\ud574 \uac10\uc5fc\uc131 \uc9c8\ud658 \uc5f0\uad6c\uac00 \uc804\ub7b5 \uacc4\ud68d\uc5d0 \ub2e4\uc2dc \ud3ec\ud568\ub418\uc5b4 \uad11\ubc94\uc704 \ud56d\ubc14\uc774\ub7ec\uc2a4\uc81c\uac00 \ucd08\uae30 \ub2e8\uacc4\ub85c \uc9c4\uc785\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ubc1c\uad74 \ub2e8\uacc4\ubcc4: 2025\ub144 \uc120\ub3c4 \ubb3c\uc9c8 \ubc1c\uad74(Lead identification)\uc774 \uc9c0\ucd9c\uc758 24.53%\ub97c \ucc28\uc9c0\ud588\uc9c0\ub9cc, \uc804\uc784\uc0c1 \ud6c4\ubcf4 \ubb3c\uc9c8 \uc120\uc815(Pre-clinical candidate selection)\uc740 2031\ub144\uae4c\uc9c0 13.85%\uc758 CAGR\ub85c \uc99d\uac00\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc2a4\ud3f0\uc11c\ub4e4\uc740 \ud6c4\uae30 \ub2e8\uacc4\uc758 \uc704\ud5d8\uc744 \uc904\uc774\uae30 \uc704\ud574 ADMET, \ub3c5\uc131\ud559 \ubc0f \uc81c\ud615\uc5d0 \ub354 \ub9ce\uc740 \uc790\uc6d0\uc744 \ud22c\uc785\ud558\uace0 \uc788\uc73c\uba70, \ub2e8\uacc4\ubcc4 \uac70\ubc84\ub10c\uc2a4\ub294 IND \uc804\uc5d0 \uc0dd\uccb4 \ub0b4 \ud6a8\ub2a5\uc744 \uc694\uad6c\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. DNA \uc778\ucf54\ub529 \ub77c\uc774\ube0c\ub7ec\ub9ac\ub294 \uc800\ube44\uc6a9\uc73c\ub85c \ud788\ud2b8 \ub2e4\uc591\uc131\uc744 \ub192\uc774\uace0, AlphaFold2\ub294 \uad6c\uc870 \uae30\ubc18 \uc124\uacc4\ub97c \uc9c0\uc6d0\ud558\uba70, CRISPR \uac80\uc99d\uc740 \ud45c\uc801 \ud544\uc218\uc131\uc744 \uc54c\ub824\uc90d\ub2c8\ub2e4.<br \/>\n*   \uc57d\ubb3c \uc720\ud615\ubcc4: \ud569\uc131 \ud654\ud569\ubb3c\uc740 2025\ub144 \uc0dd\uc0b0\ub7c9\uc758 43.63%\ub97c \ucc28\uc9c0\ud588\uc9c0\ub9cc, \ubd84\ud574\uc81c(degrader) \uae30\uc220\uc740 17.87%\uc758 CAGR\ub85c \ube60\ub974\uac8c \ubc1c\uc804\ud558\uba70 \uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5 \ub0b4\uc5d0\uc11c \uc591\uc2dd \uc804\ub7b5\uc744 \uc7ac\uc815\uc758\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. Arvinas\ub294 2024\ub144 \uc720\ubc29\uc554 3\uc0c1 \uc784\uc0c1\uc2dc\ud5d8\uc5d0 \ubcb1\ub370\uac8c\uc2a4\ud2b8\ub780\ud2b8(vepdegest\ub780\ud2b8(vepdegestrant)\ub97c \ud22c\uc785\ud588\uc2b5\ub2c8\ub2e4. \uc774\ucc98\ub7fc \ubd84\ud574\uc81c \uae30\uc220\uc740 \uae30\uc874 \uc18c\ubd84\uc790 \uc57d\ubb3c\uc758 \ud55c\uacc4\ub97c \uadf9\ubcf5\ud558\uba70 \uc0c8\ub85c\uc6b4 \uce58\ub8cc \uc635\uc158\uc744 \uc81c\uacf5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub610\ud55c, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC)\uc640 \uac19\uc740 \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c\ub3c4 \ud2b9\uc815 \uc554 \uce58\ub8cc \ubd84\uc57c\uc5d0\uc11c \uc911\uc694\ud55c \uc9c4\uc804\uc744 \ubcf4\uc774\uba70 \uc2dc\uc7a5 \uc810\uc720\uc728\uc744 \ud655\ub300\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub7ec\ud55c \ub2e4\uc591\ud55c \uc57d\ubb3c \uc720\ud615\uc758 \ubc1c\uc804\uc740 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5\uc758 \uc5ed\ub3d9\uc131\uc744 \ub354\uc6b1 \ub192\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>*   \uce58\ub8cc \uc601\uc5ed\ubcc4: \uc885\uc591\ud559\uc740 2025\ub144 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5\uc758 38.21%\ub97c \ucc28\uc9c0\ud558\uba70 \uc5ec\uc804\ud788 \uac00\uc7a5 \ud070 \ube44\uc911\uc744 \ucc28\uc9c0\ud558\uace0 \uc788\uc9c0\ub9cc, \uc2e0\uacbd\uacfc\ud559 \ubc0f \ud76c\uadc0 \uc9c8\ud658 \ubd84\uc57c\uc758 \uc5f0\uad6c \uac1c\ubc1c \ud22c\uc790\ub3c4 \uafb8\uc900\ud788 \uc99d\uac00\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud2b9\ud788 \uc54c\uce20\ud558\uc774\uba38\ubcd1\uacfc \ud30c\ud0a8\uc2a8\ubcd1 \uac19\uc740 \uc2e0\uacbd\ud1f4\ud589\uc131 \uc9c8\ud658\uc5d0 \ub300\ud55c \ubbf8\ucda9\uc871 \uc758\ub8cc \uc218\uc694\uac00 \ub192\uc544\uc9c0\uba74\uc11c, \uc774 \ubd84\uc57c\uc758 \ud601\uc2e0\uc801\uc778 \uce58\ub8cc\uc81c \uac1c\ubc1c\uc5d0 \ub300\ud55c \uae30\ub300\uac00 \ucee4\uc9c0\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc720\uc804\uc790 \uce58\ub8cc \ubc0f \uc138\ud3ec \uce58\ub8cc \uae30\uc220\uc758 \ubc1c\uc804\uc740 \ud76c\uadc0 \uc9c8\ud658 \uce58\ub8cc\uc5d0 \uc0c8\ub85c\uc6b4 \uac00\ub2a5\uc131\uc744 \uc81c\uc2dc\ud558\uba70, \ub9de\ucda4\ud615 \uc758\ud559 \uc2dc\ub300\uc758 \ub3c4\ub798\ub97c \uac00\uc18d\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uac10\uc5fc\ubcd1 \ubd84\uc57c\uc5d0\uc11c\ub294 \ud32c\ub370\ubbf9 \uc774\ud6c4 \ubc31\uc2e0 \ubc0f \ud56d\ubc14\uc774\ub7ec\uc2a4\uc81c \uac1c\ubc1c\uc758 \uc911\uc694\uc131\uc774 \ub354\uc6b1 \ubd80\uac01\ub418\uace0 \uc788\uc73c\uba70, \uc2e0\uc18d\ud55c \ub300\uc751\uc744 \uc704\ud55c \ud50c\ub7ab\ud3fc \uae30\uc220 \uac1c\ubc1c\uc5d0 \ub300\ud55c \ud22c\uc790\uac00 \ud65c\ubc1c\ud788 \uc774\ub8e8\uc5b4\uc9c0\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5\uc5d0 \ub300\ud55c \ud3ec\uad04\uc801\uc778 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \uc774 \uc2dc\uc7a5\uc740 \uc81c\uc57d, \ubc14\uc774\uc624\ud14d, \ud559\uc220 \ubc0f \uacc4\uc57d \uc5f0\uad6c \uae30\uad00(CRO)\uc774 900 \ub2ec\ud1a4 \ubbf8\ub9cc\uc758 \ud654\ud559\uc801\uc73c\ub85c \ud569\uc131\ub41c \ud654\ud569\ubb3c\uc744 \ub300\uc0c1\uc73c\ub85c \ud558\ub294 \ud45c\uc801 \uc2dd\ubcc4, \ud788\ud2b8-\ud22c-\ub9ac\ub4dc, \ub9ac\ub4dc \ucd5c\uc801\ud654 \ubc0f \uc804\uc784\uc0c1 \ud6c4\ubcf4 \ubb3c\uc9c8 \uc120\uc815 \ub2e8\uacc4\uc5d0 \uc9c0\ucd9c\ud558\ub294 \uc5f0\uac04 \ube44\uc6a9\uc73c\ub85c \uc815\uc758\ub429\ub2c8\ub2e4. \uace0\ucc98\ub9ac\ub7c9 \uc2a4\ud06c\ub9ac\ub2dd(HTS), \ub2e8\ud3b8 \uae30\ubc18 \uc2e0\uc57d \uc124\uacc4(FBDD), \uad6c\uc870 \uae30\ubc18 \uc2e0\uc57d \uc124\uacc4(SBDD), AI \uae30\ubc18 \ub9ac\uac04\ub4dc \ucd5c\uc801\ud654 \ub4f1 \ud575\uc2ec \uae30\uc220 \ud50c\ub7ab\ud3fc\uc774 \ud3ec\ud568\ub418\uba70, \uc784\uc0c1\uc2dc\ud5d8\uacc4\ud68d(IND) \uc2e0\uccad \uc804\uae4c\uc9c0\uc758 \uacfc\uc815\uc744 \ub2e4\ub8f9\ub2c8\ub2e4. IND \uc774\ud6c4 \uc784\uc0c1 \uac1c\ubc1c, \ub300\ubd84\uc790 \ud504\ub85c\uadf8\ub7a8, \uc0c1\uc5c5\uc6a9 API \uc81c\uc870 \ube44\uc6a9\uc740 \ubc94\uc704\uc5d0\uc11c \uc81c\uc678\ub429\ub2c8\ub2e4.<\/p>\n<p>1. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc804\ub9dd<br \/>\n\uc18c\ubd84\uc790 \uc2e0\uc57d \ubc1c\uad74 \uc2dc\uc7a5\uc740 2026\ub144 674.2\uc5b5 \ub2ec\ub7ec\uc5d0\uc11c 2031\ub144\uae4c\uc9c0 1030.6\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \ud2b9\ud788 \ud56d\uc554(Oncology) \ubd84\uc57c\uac00 2025\ub144 \uc2dc\uc7a5 \uc810\uc720\uc728 31.55%\ub85c \uac00\uc7a5 \ud070 \ube44\uc911\uc744 \ucc28\uc9c0\ud558\uba70, \uc815\ubc00 \uc758\ud559 \ud22c\uc790 \uc9c0\uc18d\uc744 \ubc18\uc601\ud569\ub2c8\ub2e4. \uac00\uc7a5 \ube60\ub978 \uc131\uc7a5\uc774 \uc608\uc0c1\ub418\ub294 \uce58\ub8cc \ubd84\uc57c\ub294 \uc790\uac00\uba74\uc5ed \uc9c8\ud658(Autoimmune Disorders)\uc73c\ub85c, 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 12.25%\ub97c \uae30\ub85d\ud560 \uac83\uc73c\ub85c \ubcf4\uc785\ub2c8\ub2e4. \uc57d\ubb3c \uc720\ud615\ubcc4\ub85c\ub294 PROTACs \ubc0f Molecular Glues\uac00 17.87%\uc758 \ub192\uc740 CAGR\ub85c \uc131\uc7a5\ud558\uba70, \uae30\uc874\uc5d0\ub294 \ud45c\uc801\ud654\ud558\uae30 \uc5b4\ub824\uc6e0\ub358 \ub2e8\ubc31\uc9c8\uc744 \ubd84\ud574\ud558\ub294 \ud601\uc2e0\uc801\uc778 \uc811\uadfc\ubc95\uc73c\ub85c \uc8fc\ubaa9\ubc1b\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc9c0\uc5ed\ubcc4\ub85c\ub294 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591(Asia-Pacific) \uc9c0\uc5ed\uc774 \uc911\uad6d\uc758 \uc2e0\uc57d \uc2b9\uc778 \uc99d\uac00\uc640 \uc778\ub3c4\uc758 CRO \uc5ed\ub7c9 \ud655\uc7a5\uc5d0 \ud798\uc785\uc5b4 11.21%\uc758 \uac00\uc7a5 \ube60\ub978 CAGR \uc131\uc7a5\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<\/p>\n<p>2. \uc2dc\uc7a5 \ub3d9\uc778 \ubc0f \uc81c\uc57d<br \/>\n\uc8fc\uc694 \uc2dc\uc7a5 \ub3d9\uc778\uc73c\ub85c\ub294 \ub9cc\uc131 \ubc0f \ub178\ud654 \uad00\ub828 \uc9c8\ubcd1 \ubd80\ub2f4 \uc99d\uac00, \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ub300\ube44 \uc18c\ubd84\uc790\uc758 \uc6b0\uc218\ud55c \uc81c\uc870 \uac00\ub2a5\uc131 \ubc0f \ube44\uc6a9 \ud6a8\uc728\uc131, AI \uae30\ubc18 \ud788\ud2b8-\ud22c-\ub9ac\ub4dc \ubaa8\ub378\ub9c1\uc758 \uae09\uc18d\ud55c \ubc1c\uc804, \uaddc\uc81c \ub2f9\uad6d\uc758 \uc2e0\uc18d \uc2ec\uc0ac \uc9c0\uc815\uc73c\ub85c \uc778\ud55c \uc2b9\uc778 \uac00\uc18d\ud654, \ubbf8\ub2c8-\ud50c\ub85c\uc6b0 \ud654\ud559\uc744 \ud1b5\ud55c \uc628\ub514\ub9e8\ub4dc GMP \ud569\uc131 \uac00\ub2a5\uc131, \uadf8\ub9ac\uace0 \uc591\uc790 \ucef4\ud4e8\ud305 \ubd84\uc790 \uc2dc\ubbac\ub808\uc774\uc158\uc758 \ud601\uc2e0\uc801\uc778 \ubc1c\uc804\uc774 \uaf3d\ud799\ub2c8\ub2e4.<br \/>\n\ubc18\uba74, \uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778\uc73c\ub85c\ub294 \uc2e0\uc57d \uac1c\ubc1c \ud6c4\uae30 \ub2e8\uacc4\uc5d0\uc11c\uc758 \uc2e4\ud328\uc728 \uc99d\uac00 \ubc0f \ube44\uc6a9 \uc778\ud50c\ub808\uc774\uc158, \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ubc0f \ucca8\ub2e8 \uce58\ub8cc\ubc95\uc73c\ub85c\uc758 \uc790\ubcf8 \uc804\ud658, \ud569\uc131 \uacfc\uc815\uc758 \uc6a9\ub9e4 \ubc30\ucd9c\uc5d0 \ub300\ud55c \ud658\uacbd\u00b7\uc0ac\ud68c\u00b7\uc9c0\ubc30\uad6c\uc870(ESG) \uac10\uc2dc \uac15\ud654, \uadf8\ub9ac\uace0 \ud76c\uadc0 \uad11\uc0b0\ud654 \ucd09\ub9e4\uc758 \uacf5\uae09 \uc704\ud5d8 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>3. \uae30\uc220 \ubc0f \uacbd\uc7c1 \ud658\uacbd<br \/>\n\uae30\uc220\uc801 \uce21\uba74\uc5d0\uc11c\ub294 \uc778\uacf5\uc9c0\ub2a5(AI) \uae30\ubc18 \ud50c\ub7ab\ud3fc\uc774 \uc2e0\uc57d \ubc1c\uad74 \uae30\uac04\uc744 \ud68d\uae30\uc801\uc73c\ub85c \ub2e8\ucd95\uc2dc\ud0a4\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc608\ub97c \ub4e4\uc5b4, AI-native \ud50c\ub7ab\ud3fc\uc740 \ud45c\uc801 \uc2dd\ubcc4\ubd80\ud130 IND \uc2e0\uccad\uae4c\uc9c0\uc758 \uae30\uac04\uc744 \ucd5c\ub300 40%\uae4c\uc9c0 \ub2e8\ucd95\uc2dc\ud0a8 \uc0ac\ub840(REC-1245)\ub97c \ubcf4\uc5ec\uc8fc\uba70, \uc774\ub294 \uc2e0\uc57d \uac1c\ubc1c\uc758 \ud6a8\uc728\uc131\uc744 \ud06c\uac8c \ud5a5\uc0c1\uc2dc\ud0a4\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n\uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d\uc5d0\ub294 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4, \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d, \uadf8\ub9ac\uace0 AstraZeneca, Atomwise Inc., BenevolentAI, Charles River Laboratories, Pfizer Inc., Recursion Pharmaceuticals, Schrodinger Inc., WuXi AppTec \ub4f1 22\uac1c \uc8fc\uc694 \uae30\uc5c5\uc758 \ud504\ub85c\ud544\uc774 \ud3ec\ud568\ub429\ub2c8\ub2e4.<\/p>\n<p>4. \uc5f0\uad6c \ubc29\ubc95\ub860<br \/>\n\ubcf8 \ubcf4\uace0\uc11c\ub294 1\ucc28 \uc5f0\uad6c(\uc758\uc57d \ud654\ud559\uc790, CRO \uc784\uc6d0, \ud559\uc220 \uc5f0\uad6c\uc790 \ub4f1\uacfc\uc758 \uc2ec\uce35 \uc778\ud130\ubdf0)\uc640 2\ucc28 \uc5f0\uad6c(\ubbf8\uad6d FDA \uc2b9\uc778 \uae30\ub85d, NIH ClinicalTrials.gov, OECD R&#038;D \uc9c0\ucd9c \ud1b5\uacc4, WIPO \ud2b9\ud5c8 \ud3ec\ud138, \uae30\uc5c5 \ubcf4\uace0\uc11c \ub4f1)\ub97c \uacb0\ud569\ud558\uc5ec \ub370\uc774\ud130\ub97c \uc218\uc9d1\ud558\uace0 \uac80\uc99d\ud588\uc2b5\ub2c8\ub2e4. \uc2dc\uc7a5 \uaddc\ubaa8\ub294 \uc0c1\ud5a5\uc2dd \ubc0f \ud558\ud5a5\uc2dd \uc811\uadfc \ubc29\uc2dd\uc744 \ud1b5\ud574 \uc0b0\uc815\ub418\uc5c8\uc73c\uba70, \uce58\ub8cc \ubd84\uc57c\ubcc4 \uc784\uc0c1 \ud30c\uc774\ud504\ub77c\uc778 \uc218, \ud788\ud2b8-\ud22c-\ub9ac\ub4dc \uc804\ud658\uc728, \ud3c9\uade0 \uac1c\ubc1c \uc8fc\uae30, \uc778\ud50c\ub808\uc774\uc158 \uc870\uc815 \ud654\ud559 \ub178\ub3d9 \ube44\uc6a9, \ud2b9\ud5c8 \ucd9c\uc6d0 \ubc00\ub3c4, CRO \uc544\uc6c3\uc18c\uc2f1 \uce68\ud22c\uc728 \ub4f1 \ub2e4\uc591\ud55c \ubcc0\uc218\ub97c \uace0\ub824\ud558\uc5ec \uc608\uce21 \ubaa8\ub378\uc744 \uad6c\ucd95\ud588\uc2b5\ub2c8\ub2e4. \ub370\uc774\ud130\ub294 \ub9e4\ub144 \uc5c5\ub370\uc774\ud2b8\ub418\uba70, \uc8fc\uc694 \uc0ac\uac74 \ubc1c\uc0dd \uc2dc \uc911\uac04 \uc5c5\ub370\uc774\ud2b8\uac00 \uc774\ub8e8\uc5b4\uc9d1\ub2c8\ub2e4.<\/p>\n<p>5. \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd<br \/>\n\ubcf4\uace0\uc11c\ub294 \ubbf8\ucda9\uc871 \uc218\uc694 \ud3c9\uac00\ub97c \ud1b5\ud574 \uc2dc\uc7a5\uc758 \uc7a0\uc7ac\uc801 \uae30\ud68c\ub97c \uc2dd\ubcc4\ud558\uace0, \ud5a5\ud6c4 \uc2dc\uc7a5\uc758 \ubc1c\uc804 \ubc29\ud5a5\uc744 \uc81c\uc2dc\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-37351","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/37351"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=37351"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/37351\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=37351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=37351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=37351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}